R&D News

R&D News

  • November 5, 2025 Pipeline ― State of New Product Development
  • October 23, 2025 Receipt of Complete Response Letter from U.S. FDA for investigational ND0612 pdf （199KB）
  • October 14, 2025 Anti-CD19 monoclonal antibody UPLIZNA® for I.V. Infusion 100mg Application for additional indication of generalized Myasthenia Gravis in Japan pdf （582KB）
  • August 1, 2025 Pipeline ― State of New Product Development
  • July 10, 2025 To initiate joint research aiming to create innovative cancer drugs in Targeted Alpha Therapy pdf （458KB）
  • June 13, 2025 Initiation of Phase 1/2 clinical trial of MT-4561 for Advanced Solid Tumors pdf （266KB）
  • May 29, 2025 U.S. FDA Accepts Resubmission for ND0612, an Investigational Treatment for Motor Fluctuations in Parkinson’s Disease pdf （205KB）
  • May 13, 2025 Pipeline ― State of New Product Development
  • March 21, 2025 Anti-CD19 monoclonal antibody UPLIZNA® for I.V. Infusion 100mg Application for additional indication of immunoglobulin G4-related disease in Japan pdf （436KB）
  • March 13, 2025 Filling for a Oral Edaravone Formulation for the treatment of ALS in Korea pdf （174KB）
  • February 21, 2025 EMA Accepts Marketing Authorization Application for ND0612, an Investigational Treatment for Motor Fluctuations in Parkinson’s Disease pdf （223KB）
  • February 6, 2025 Pipeline ― State of New Product Development
  • December 5, 2024 Mitsubishi Tanabe Pharma Corporation Entered into Research Collaboration with Dewpoint to Advance Small Molecule Condensate Modulator for ALS
  • November 1, 2024 Pipeline ― State of New Product Development
  • November 1, 2024 Update on U.S. Development Plan of Investigational ND0612 for the Treatment of Motor Fluctuations in People with Parkinson’s Disease
  • August 1, 2024 Pipeline ― State of New Product Development
  • June 11, 2024 Receipt of Complete Response Letter from U.S. FDA for ND0612
  • May 15, 2024 Pipeline ― State of New Product Development
  • May 9, 2024 The Global Health Innovative Technology Fund provides grant to Mitsubishi Tanabe Pharma and DNDi for Chagas disease drug discovery
  • April 9, 2024 RADICAVA ORS® as Orphan drug designation and approval in US
  • March 19, 2024 Announcement of Publication in The Lancet Neurology from the Clinical Study of Investigational ND0612 for Parkinson's Disease
  • March 18, 2024 Additional Approval of SGLT2 inhibitor CANAGLU® OD Tablets～First OD Tablets of SGLT2 inhibitors in Japan～
  • February 6, 2024 Pipeline ― State of New Product Development
  • December 7, 2023 The mechanism of intracellular glucose uptake of SGLT2 was elucidated by Cryo-electron Microscopy analysis in a joint study with the University of Tokyo Published in Nature Structural & Molecular Biology
  • November 8, 2023 Mitsubishi Tanabe Pharma Corporation Entered into License Agreement with Kynexis for Neuropsychiatric Drug Candidate “MT-5356”
  • November 1, 2023 Pipeline ― State of New Product Development
  • October 25, 2023 A Global Phase 3 Clinical Trial of MT-2111 in Combination with Rituximab has been started in Japan
  • October 18, 2023 MT-2111 in Phase 2 part of Phase 1/2 Clinical Trial in Diffuse Large B-cell Lymphoma in Japan
  • September 27, 2023 The Global Health Innovative Technology Fund provides grant for joint research into anti-malarial drugs with novel mechanisms of action conducted by Mitsubishi Tanabe Pharma and a malaria research institution
  • August 2, 2023 Pipeline ― State of New Product Development
  • August 1, 2023 Global, Phase 3b study of Oral Edaravone in ALS
  • May 31, 2023 AnGes filed for approval of its HGF gene therapy product Collategene® for the first time since the introduction of the conditional/time-limited authorization system for regenerative medicine products
  • May 12, 2023 Pipeline ― State of New Product Development
  • May 11, 2023 RADICAVA® Oral Suspension Approved in Switzerland for the Treatment of ALS
  • March 27, 2023 Anti-cytomegalovirus chemotherapeutic agent "Valixa® Dry Syrup 5000mg" Approved for the indication of symptomatic congenital cytomegalovirus infection in Japan
  • March 27, 2023 Approval of "GOBIK Aqueous Suspension Syringes", Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine
  • March 20, 2023 Notification of Application for Additional Dosage Form of SGLT2 inhibitor CANAGLU® OD Tablets 100 mg
  • February 7, 2023 Pipeline ― State of New Product Development
  • January 10, 2023 Announcement of Positive Results from the Phase 3 Clinical Trials of Parkinson's Disease Drug Candidate ND0612
  • December 23, 2022 For Treatment of ALS, Edaravone RADICUT® Oral Suspension 2.1% Approved in Japan
  • November 24, 2022 GARDP and Mitsubishi Tanabe Pharma Corporation announce partnership in search for new antibiotics
  • November 9, 2022 RADICAVA® Oral Suspension Approved in Canada for the Treatment of ALS
  • November 8, 2022 Pipeline ― State of New Product Development
  • October 17, 2022 Inebilizumab has received import and marketing permission in Taiwan for Neuromyelitis Optica Spectrum Disorder
  • August 3, 2022 Pipeline ― State of New Product Development
  • June 30, 2022 Anti-cytomegalovirus chemotherapeutic agents "Valixa® Dry Syrup 5000mg" Notification of application for additional indication of symptomatic congenital cytomegalovirus infection in Japan
  • June 21, 2022 CANAGLU® Tablets 100mg Approved for the Indication of Chronic Kidney Disease Complicated with Type 2 Diabetes Mellitus in Japan
  • May 13, 2022 Pipeline ― State of New Product Development
  • May 13, 2022 New Japan-originated ALS treatment option available to patients in the U.S.―FDA approval of RADICAVA ORS® for the treatment of ALS
  • April 25, 2022 Swissmedic has accepted the filling for a New Oral Edaravone Formulation for the treatment of ALS
  • April 11, 2022 Marketing Authorization Application of Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine (BK1310/MT-2355)
  • April 4, 2022 Long-Term Safety Profile from Phase 2b Clinical Trials of Parkinson's Disease Drug Candidate (ND0612) Presents at 2022 American Academy of Neurology Annual Meeting
  • March 28, 2022 Regulatory Approval of DYSVAL®capsules 40mg for Treatment of Tardive Dyskinesia in Japan
  • March 14, 2022 Submission of Oral Edaravone Formulation, MT-1186 New Drug Application in Japan for the Treatment of ALS
  • February 25, 2022 Progress of Innovative Drug Discovery Research Collaboration with HitGen
  • February 24, 2022 COVID-19 vaccine, "COVIFENZ®"(MT-2766) has been approved in Canada.
  • February 3, 2022 Pipeline ― State of New Product Development
  • February 2, 2022 Regulatory Approval of Cariprazine (MP-214) for Bipolar Disorder in Singapore
  • January 18, 2022 Mitsubishi Tanabe Pharma Corporation Enters into Exclusive License Agreement with ADC Therapeutics to Develop and Commercialize Loncastuximab Tesirine, Anti-CD19 Antibody Drug Conjugate ("ADC"), for Cancer in Japan
  • January 13, 2022 FDA Acceptance of New Drug Application for Oral Edaravone Formulation for the Treatment of ALS
  • December 17, 2021 MT-2766, the world's first plant-based COVID-19 vaccine candidate Application for approval was submitted in Canada.
  • December 10, 2021 Global Phase 3 Safety Study Results of Investigational Oral Edaravone MT-1186 in the treatment of ALS
  • December 7, 2021 MT-2766, Adjuvanted COVID-19 Vaccine Candidate, Showed Positive Efficacy and Safety Results in Phase 3 Study Conducted in an Environment Dominated by the Variants
  • November 2, 2021 Pipeline ― State of New Product Development
  • October 8, 2021 Top-line data of J-KINECT Study, Phase 2/3 study in Japan of VMAT2 inhibitor MT-5199 in TD, presented at the 31st annual meeting of the Japanese Society of Clinical Neuropsychopharmacology
  • September 30, 2021 Start of a Japanese Clinical Study of MT-2766, Adjuvanted COVID-19 Vaccine Candidate
  • September 8, 2021 Phase 2 Trial of MT-3921 Initiated for Treatment of Spinal Cord Injury
  • August 5, 2021 Inebilizumab has been approved in South Korea for Neuromyelitis Optica Spectrum Disorder
  • August 4, 2021 Application for approval of CANAGLU® Tablets 100mg for the indication of chronic kidney disease with type 2 diabetes mellitus in Japan
  • August 4, 2021 MT-3921 Granted FDA Fast Track Designation for Treatment of Spinal Cord Injury
  • August 4, 2021 Pipeline ― State of New Product Development
  • May 25, 2021 Establishment of AI Technologies for Drug Screening To Accelerate Data-Driven Drug Discovery
  • May 19, 2021 Initiatives Against COVID-19 in Canada - Achieved Positive Interim Phase 2 Results for adjuvanted COVID-19 vaccine candidate -
  • May 12, 2021 Discontinuation of the Development of Nucleic Acid Products "MT-5745 (STNM01)" for Ulcerative Colitis and an Impairment Loss (non-recurring item)
  • May 12, 2021 Pipeline ― State of New Product Development
  • April 26, 2021 Initiatives Against COVID-19 in Canada - Health Canada Initiates the Review of the Rolling Submission for COVID-19 VLP Vaccine Candidate -
  • April 22, 2021 Notification of Marketing Authorization Application of Valbenazine (MT-5199) for the Treatment of Tardive Dyskinesia in Japan
  • April 8, 2021 Mitsubishi Tanabe and Mineralys entered into the exclusive License Agreement for a cardiovascular agent “MT-4129” and FDA Accepts IND Application
  • March 31, 2021 Phase -2 Clinical Trial of MT-7117 Initiated in the U.S., Canada, and Europe for the Rare Disease, Diffuse Cutaneous Systemic Sclerosis (dcSSc)
  • March 31, 2021 The Global Health Innovative Technology Fund provides grant to Mitsubishi Tanabe Pharma and DNDi for Chagas disease and leishmaniasis drug discovery ～Targeting treatments for infectious diseases that impact people in developing countries～
  • March 23, 2021 Manufacturing and Marketing Approval of UPLIZNA® for I.V. Infusion 100mg for the Treatment of Neuromyelitis Optica Spectrum Disorder in Japan
  • March 17, 2021 Initiatives Against COVID-19 in Canada - Initiate Phase 3 Portion of Phase 2/3 Clinical Trials and Fast Track Designation Granted by FDA -
  • March 3, 2021 Establish NeuroDiscovery Lab in the Boston Area to Strengthen the Discovery of Drug Targets for the Central Nervous System Disorders
  • February 26, 2021 Canagliflozin (TA-7284) has been approved in Taiwan For Diabetic Nephropathy
  • February 3, 2021 Results of J-KINECT Study,Phase 2/3 study in Japan of VMAT2 inhibitor MT-5199 in tardive dyskinesia
  • February 3, 2021 Pipeline ― State of New Product Development
  • January 26, 2021 Mitsubishi Tanabe Pharma and Pharma Foods International Enter into an Exclusive Licensing Agreement for a New Therapeutic Antibody to treat Autoimmune Diseases
  • January 18, 2021 Mitsubishi Tanabe Pharma and TAKEDA Share Internal Experimental Data to Accelerate Data-Driven Drug Discovery
  • November 16, 2020 Initiatives Against COVID-19 in Canada - Initiate Phase 2/3 Clinical Trials of VLP Vaccine Candidate -
  • November 11, 2020 Initiatives Against COVID-19 in Canada - Phase 1 Results for COVID-19 Vaccine Candidate -
  • November 4, 2020 Changes in Continuous Subcutaneous Liquid levodopa/carbidopa Administration (ND0612) for patients with fluctuating Parkinson’s disease Development Plan and an Impairment Loss (Non-recurring Items)
  • November 4, 2020 Pipeline ― State of New Product Development
  • October 26, 2020 Initiatives Against COVID-19 in Canada - Reached Agreements with Government of Canada to Receive Development Funding and Supply VLP Vaccine -
  • October 8, 2020 Canagliflozin (TA-7284) has been approved in Indonesia for Type2 Diabetes Mellitus
  • July 16, 2020 As the First ALS Treatment in Indonesia RADICAVA has been approved first in ASEAN countries
  • July 15, 2020 Initiatives Against COVID-19 in Canada - Initiated Phase 1 Clinical Trials of VLP Vaccine Candidate
  • July 8, 2020 Announcement of Collaboration between Medicago and GSK in the Development of COVID-19 Vaccine and the Start of Phase 1 Clinical Trials
  • June 29, 2020 Manufacturing and Marketing Approval of VAFSEO® Tablets (HIF-PH inhibitor, vadadustat) for renal anemia in Japan
  • June 26, 2020 Notification of Marketing Authorization Application for Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder in Japan
  • June 15, 2020 Start of a Phase 3 Clinical Trial of MT-7117 for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)
  • May 25, 2020 Regulatory Approval of Thailand for Marketing Teneligliptin (MP-513)， a treatment agent for type 2 diabetes mellitus
  • May 18, 2020 Initiatives Against COVID-19 in Canada -Intermediary Results of VLP Vaccine Pre-clinical Study pdf （353KB）
  • April 28, 2020 Notification of Changes in the U.S. Development Plan of VLP Vaccine for Seasonal Influenza Prevention (MT-2271) and an Impairment Loss (Non-recurring Items)
  • March 25, 2020 STELARA® (ustekinumab) Now Approved for the Treatment of Adults with Moderate-to-Severe Ulcerative Colitis in Japan
  • March 12, 2020 Medicago, a subsidiary in Canada, is tackling with COVID-19, coronavirus
  • November 25, 2019 Mitsubishi Tanabe Pharma Announces the Start of a Phase 3 Clinical Trial using Oral Suspension of Edaravone for ALS pdf （412KB）
  • November 11, 2019 Mitsubishi Tanabe Pharma Corporation Announces Results of the MT-7117 ENDEAVOR Study for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) pdf （367KB）
  • November 11, 2019 HIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 results for the treatment of renal anemia at American Society of Nephrology, Kidney Week 2019 pdf （466KB）
  • October 25, 2019 Vadadustat (MT-6548) Japan Phase 3 results for treatment of renal anemia to be presented at ASN Kidney Week 2019 pdf （433KB）
  • October 9, 2019 Mitsubishi Tanabe Pharma enters into a licensing agreement with Viela Bio for inebilizumab, a treatment agent for neuromyelitis optica spectrum disorder, in Japan and other Asian regions pdf （61KB）
  • October 2, 2019 Notification of acceptance of the New Drug Submission for Scientific Review of VLP Seasonal Influenza Vaccines（MT-2271）by Health Canada pdf （519KB）
  • September 30, 2019 Mitsubishi Tanabe Pharma to participate in new screening program through the Global Health Innovative Technology Fund ～Targeting treatments for infectious diseases that burden the developing countries～ pdf （378KB）
  • September 24, 2019 NMPA accepts our filing for TENELIA, a treatment agent for type 2 diabetes mellitus in China pdf （482KB）
  • August 28, 2019 The Start of a Phase 3 Clinical Trial of Continuous Subcutaneous Liquid levodopa/carbidopa Administration (ND0612) for patients with fluctuating Parkinson’s disease
  • August 8, 2019 PhaseⅠClinical Trial study protocol for MT-3921 in Patients with Spinal Cord Injury submitted to the US IND
  • August 8, 2019 Regulatory Approval for Marketing Cariprazine (MP-214) for the Treatment of Schizophrenia in Part of the ASEAN (Singapore and Thailand)
  • August 7, 2019 NMPA approved Japan-originated ALS treatment Edaravone in China
  • July 23, 2019 Submission of Vadadustat (MT-6548) New Drug Application in Japan for renal anemia
  • May 30, 2019 Withdrawal of Marketing Authorization Application of edaravone for ALS in the European Union
  • April 26, 2019 Mitsubishi Tanabe Pharma and Salix enter into a licensing agreement for MT-1303, a therapeutic agent for autoimmune diseases
  • April 26, 2019 Medicago Awarded "Best New Vaccine Technology/Platform" at the World Vaccine Congress
  • April 11, 2019 Notice Regarding Reorganization of Research, Production, and Technology Bases
  • March 28, 2019 The Global Health Innovative Technology Fund provides grant for joint research into anti-malarial drugs conducted by Mitsubishi Tanabe Pharma and a malaria research institution
  • March 26, 2019 AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia
  • March 12, 2019 Topline Results of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Anemia due to CKD
  • February 14, 2019 FDA accepted an Investigational New Drug Application for MT-8633, an ADC Targeting cMet Positive Solid Tumors
  • February 6, 2019 Swissmedic approves RADICAVA, Japan-originated ALS treatment
  • December 11, 2018 HitGen and Mitsubishi Tanabe Pharma Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
  • December 10, 2018 Conduct a study to identify and measure specific biomarkers in ALS - we will strive to deliver a beneficial therapy option to patients -
  • November 15, 2018 Mitsubishi Tanabe Pharma to present New data on Investigational Oral Suspension of Edaravone for ALS at 29th International Symposium on ALS/MND
  • October 22, 2018 Strategic Research Collaboration for the Development of Innovative Antibody Drug to Treat Autoimmune Diseases pdf （238KB）
  • October 9, 2018 Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Announce Second Public Recruitment Offering of "JOINUS®", a Joint Research Program to Discover New Drugs using Drug-Repositioning Compound Library
  • October 5, 2018 For the ALS patients in Canada, we hope to deliver Japan-originated ALS treatment ―Health Canada approves RADICAVA™ (edaravone) for the treatment of ALS
  • July 27, 2018 Mitsubishi Tanabe Pharma's MT-7117 Receives U.S. FDA Fast Track Designation for the Investigational Treatment of Patients with the Ultra-Rare Disease, Erythropoietic Protoporphyria
  • July 19, 2018 Mitsubishi Tanabe Pharma Receives The 43rd (FY2018) Inoue Harushige Prize ― A challenge for the new drug against amyotrophic lateral sclerosis (ALS), research and development of edaravone―
  • July 2, 2018 Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science” - Toward the Innovative Drug Discovery for refractory Neurological Diseases -
  • July 2, 2018 Open Call for Applicants for Researcher-Initiated Clinical Research Funds - We Ensure Transparency and Support Investigator-Initiated Research Based on Japan's Clinical Research Act -
  • June 14, 2018 TFDA approves Clenafin/Jublia for the treatment of Onychomycosis in Taiwan
  • May 30, 2018 Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development―Start of collaborative/competitive drug discovery research by three academic institutions and three pharmaceutical companies
  • May 28, 2018 For the ALS patients in the world, we hope to deliver Japan-originated ALS treatment―EMA accepts our filing for Edaravone to treat ALS
  • May 18, 2018 Canagliflozin (Antidiabetic agent) wins The Technology Award Grand Prize from the Japan Chemical Industry Association (JCIA)
  • April 10, 2018 To ALS patients in the world, we hope to deliver Japan-originated ALS treatment―Health Canada accepts our filing for Edaravone to treat ALS and we established commercializing company in Canada
  • March 26, 2018 Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development
  • February 28, 2018 Valixa® Tablet 450mg ―Public knowledge-based application for an additional pediatric indication for the prevention of CMV disease in organ transplant patients as well as application for an additional dosage form of dry syrup
  • January 23, 2018 Swissmedic accepts our filing for Edaravone to treat ALS ― To ALS patients in the world, we hope to deliver Japan-originated ALS treatment
  • January 16, 2018 Approval in China Received for Additional Novastan® Indication for Acute Cerebral Infarction ― Reinforcing Our Pharmaceutical Development and Sales in China, the World's Second Largest Pharmaceutical Market
  • January 11, 2018 Launch of "KREMEZIN® Tablets 500mg" (Additional Formulation), Drug for Chronic Renal Failure ― For Improving Patients' Usage Experience and Medication Adherence ―
  • December 13, 2017 Strategic Collaboration for the Development of the Antibody Drug to Treat Neurodegenerative Diseases including ALS
  • November 1, 2017 Notice Regarding Mitsubishi Tanabe Pharma’s Acquisition of Stelic Institute & Co., Inc. Securing Nucleic Acid Pharmaceuticals of Inflammatory bowel disease for Future Launch in the U.S.
  • November 1, 2017 Notice of the Start of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Renal Anemia
  • October 11, 2017 Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library -Three Japanese pharmaceutical companies collaborate in facilitating drug discovery in Japan through open innov
  • September 27, 2017 Notice regarding acquisition of manufacturing and sales approval for Rupafin® tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)
  • September 27, 2017 Notice of the Start of Phase 3 Clinical Study of VLP Seasonal Influenza Vaccine
  • August 17, 2017 Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis pdf （340KB）
  • July 27, 2017 Notice regarding the initiation of a phase 2/3 clinical trial in Japan for tardive dyskinesia patients for VMAT2 inhibitor MT-5199
  • July 3, 2017 Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug ―Application approved in Japan for CANALIA® Combination Tablets, a type 2 diabetes mellitus treatment agent -Combination of selective DPP-4 inhibitor TENELIA® Tablets and SGLT2 inhibitor CANAGLU® Tablets-
  • June 1, 2017 Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund’s second phase ―Targeting treatments for infectious diseases that burden the developing world―
  • May 18, 2017 Approval for partial change in administration / dosage for Crohn’s disease for REMICADE® for I.V. Infusion 100, an anti-human TNFα monoclonal antibody
  • May 16, 2017 Mitsubishi Tanabe Pharma announces The Lancet Neurology publication of the positive clinical results of Edaravone for ALS
  • May 8, 2017 New Japan-originated ALS treatment option available to patients in the U.S. ―U.S. FDA approves RADICAVA™ (edaravone) for the treatment of ALS
  • April 24, 2017 Mitsubishi Tanabe Pharma Group receives import and marketing permission in Taiwan for CANAGLU® Tablets 100mg, a treatment agent for type 2 diabetes mellitus
  • March 30, 2017 Notice regarding approval of indication of ulcerative colitis and additional formulation for SIMPONI® subcutaneous injection 50mg syringe (generic name: golimumab), a human monoclonal antibody specific for human TNF α
  • January 27, 2017 Biogen and Mitsubishi Tanabe Pharma Terminate the License Agreement on MT-1303
  • December 9, 2016 12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Symposium on ALS/MND pdf （104KB）
  • November 1, 2016 Mitsubishi Tanabe Pharma Takes on the Challenge of Cell Therapy with the Conclusion of an Invossa Licensing Agreement with Kolon Life Science Aiming for therapy that addresses unmet medical needs in the treatment of knee osteoarthritis
  • October 5, 2016 Joint research identifies hit compounds for the development of a new treatment for malaria Mitsubishi Tanabe Pharma uses its compound library in joint research activities with Medicines for Malaria Venture ―Targeting treatments for infectious diseases that burden the developing world―
  • September 6, 2016 Application for partial change in administration/dosage for Crohn's disease for REMICADE® for I.V. Infusion 100, an anti-human TNFα monoclonal antibody
  • August 30, 2016 FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS
  • August 26, 2016 Valixa® Tablet 450mg Approval for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients
  • August 23, 2016 Application filed in Japan fortype 2 diabetes mellitus treatment agent combination drug - Combination of selective DPP-4 inhibitor TENELIA® Tablets and SGLT2 inhibitor CANAGLU® Tablets -
  • June 20, 2016 Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States
  • June 6, 2016 Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund
  • May 13, 2016 Approval of REMICADE® for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, for a Partial Change in Dosage and Usage in Psoriasis
  • April 20, 2016 Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting pdf （301KB）
  • March 29, 2016 Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Libraries
  • March 22, 2016 Valixa® Tablet 450 mg Application for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients Public Knowledge-based Application
  • December 21, 2015 Remicade® for I.V. Infusion 100 Approval of Additional Indication for Kawasaki Disease World First Biologic Treatment
  • December 15, 2015 Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia
  • November 20, 2015 Announcement of an approval for an additional indication for the Anti-depressant, Lexapro® Tablets 10 mg in Japan
  • October 30, 2015 Medicago Engaged by the Canadian Government Produce Ebola Monoclonal Antibodies
  • October 2, 2015 Mitsubishi Tanabe Pharma and Regeneron Conclude Collaboration Agreement for Fasinumab, NGF Antibody
  • September 23, 2015 MedImmune and Tanabe Research Laboratories / Mitsubishi Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat Cancer
  • September 17, 2015 Notice Regarding Worldwide Patent and Know-how Transfer, Excluding Japan and Certain Other Territories in Asia, for TA-8995 (CETP inhibitor), a Treatment Agent for Dyslipidemia
  • September 15, 2015 MT-4666 in Alzheimer’s Disease Discontinuation of Global Phase 3 Clinical Trial Program in Japan
  • September 9, 2015 Biogen and Mitsubishi Tanabe Pharma Conclude a License Agreement on MT-1303, a Therapeutic Agent for Autoimmune Diseases
  • August 24, 2015 Approval of REMICADE® for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, for Additional Indications for Entero-Behcet's Disease, Neuro-Behcet's Disease, and Vasculo-Behcet's Disease
  • July 10, 2015 Application Filed for a Partial Change in Dosage and Usage of REMICADE® for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, in Psoriasis
  • June 26, 2015 RADICUT® inj. 30mg and RADICUT® BAG for I.V. Infusion 30mg Mitsubishi Tanabe Pharma Corporation receives approval for additional indication for Amyotrophic Lateral Sclerosis (ALS) in Japan
  • May 26, 2015 Approval for Additional Pediatric Indications in Japan Received for TALION® Tablets and TALION® OD Tablets, Anti-Allergic Agents
  • May 22, 2015 Mitsubishi Tanabe Pharma provides Compound Library to Screening Program of Global Health Innovative Technology Fund
  • April 1, 2015 Execution of License Agreement on VMAT2 Inhibitor NBI-98854
  • February 25, 2015 Medicago Develops Alternative Production Process for Ebola Antibodies Contract concluded with U.S. government
  • February 25, 2015 Reorganization of research bases in Japan
  • November 13, 2014 Application filed for additional indication for ALS for RADICUT® inj. 30mg and RADICUT BAG for I.V. Infusion 30mg
  • October 30, 2014 Applications filed for REMICADE® for I.V. Infusion 100, an anti-human TNFα monoclonal antibody, for additional indications for entero-Behcet’s disease, neuro-Behcet’s disease, and vasculo-Behcet’s disease
  • September 19, 2014 TELAVIC® 250mg Tablets, Antiviral Approval of Additional indication for Chronic Hepatitis C Genotype 2
  • August 20, 2014 MITSUBISHI TANABE PHARMA CORPORATION AND ASTRAZENECA ANNOUNCE RESEARCH COLLABORATION IN DIABETIC NEPHROPATHY
  • July 4, 2014 Marketing and Manufacturing Approval in Japan Received for CANAGLU® Tablets 100mg
  • June 16, 2014 Positive Phase 3 Results of Canagliflozin in Japanese Patients with Type 2 Diabetes at American Diabetes Association
  • February 3, 2014 MT-4666 in Alzheimer’s DiseaseStart of Global Phase 3 Clinical Trial Program, COGNITIV AD
  • January 16, 2014 TELAVIC® 250mg Tablets, Antiviral Application for additional Indication for Chronic Hepatitis C Genotype 2
  • December 20, 2013 TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy
  • June 27, 2013 VIVUS gains MAA approval for TA-1790 in the EU
  • June 14, 2013 Approval for Additional Indication for Atrial Fibrillation (Tachycardiac ) MAINTATE® Tablets: Selective β1 Blocker
  • May 27, 2013 New Drug Application Filed in Japan for TA-7284 (Canagliflozin) To Treat Patients with Type 2 Diabetes
  • April 1, 2013 U.S. FDA Approves Canagliflozin (TA-7284) for the Treatment of Adult Patients with Type 2 Diabetes
  • February 28, 2013 Approval for time-window extension of the thrombolytic agents GRTPA® and ACTIVACIN® up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular disease
  • February 26, 2013 TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Application for Partial Change in Indications for Combination Therapy
  • February 21, 2013 Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitor
  • January 29, 2013 BindRen® Granted Marketing Authorization in Europe for Treatment of Hyperphosphatemia
  • October 10, 2012 Outcome of Global Phase III (EPPIC) Studies
  • September 28, 2012 Application for time-window extension of the thrombolytic agents GRTPA® and ACTIVACIN® up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular disease
  • September 13, 2012 MAINTATE® Tablets: Selective β1 AntagonistNotice regarding application for additional indication for chronic atrial fibrillation
  • August 31, 2012 Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole
  • June 29, 2012 Marketing and Manufacturing Approval Received for TENELIA® 20mg Tablets A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan
  • June 1, 2012 Termination of License Agreement with Cytochroma for MT-2832 (Generic Name: Lunacalcipol) as a Treatment for Secondary Hyperparathyroidism
  • May 7, 2012 VIVUS gains NDA approval for TA-1790 in the US
  • March 7, 2012 Conclusion of Research Collaboration Agreement for Next-Generation Vaccines
  • January 16, 2012 Conclusion of Licensing Agreement for Hib Vaccine
  • November 25, 2011 Approval of Additional Indication for MODIODAL® Tablets 100 mg a Sleep Disorder Treatment
  • October 14, 2011 Toray, Mitsubishi Tanabe Pharma Reach North American License Agreement on Antipruritic Agent, TRK-820
  • September 26, 2011 Approval for "IMUSERA® Capsules 0.5mg" Japan's First Once-Daily Oral Dosing Multiple Sclerosis Treatment
  • September 26, 2011 Approval for TELAVIC® 250mg Tablet Novel Mode of Action for Chronic Hepatitis C Treatment
  • September 26, 2011 Approval for Additional Indication of Generalized Myasthenia Gravis Venoglobulin® IH 5% for Intravenous Injection, a Human Immunoglobulin Preparation Derived from Donated Plasma
  • September 1, 2011 New Drug Application Filed in Japan for MP-513 a Type 2 Diabetes Treatment
  • August 17, 2011 Remicade® for I.V. Infusion 100, Anti-Human TNF α Monoclonal-Antibody Approval for a Partial Change of Dosage and Usage in Crohn’s Disease
  • July 1, 2011 Approval for "SIMPONI® Subcutaneous Injection 50mg Syringe (Generic Name: Golimumab)" for Treatment of Rheumatoid Arthritis
  • June 2, 2011 AZANIN® Tablets 50mg, Immunosuppressant Approval for Additional Indication for Refractory Rheumatic Diseases
  • May 20, 2011 Approval for Additional Indication for selective β1 antagonist, MAINTATE® Tablets 0.625, 2.5, and 5 and Launch of MAINTATE® Tablets 0.625
  • May 20, 2011 Approval for Additional Indications for the Selective Antithrombin Agents, Novastan® HI Injection 10 mg/2mL and Slonnon® HI Injection 10 mg/2mL
  • May 20, 2011 Approval for Additional Indication of Anti-D Human Immunoglobulin I.M.1000-BENESIS (Dry anti-Rho(D) Immune Human Globulin)
  • March 28, 2011 Novartis receives European Commission approval for FTY720, the first oral multiple sclerosis treatment for use in the EU
  • March 11, 2011 Open innovation laboratory for drug discovery and development by Mitsubishi Tanabe Pharma and Kyoto University -Basic and clinical research project for CKD drugs-
  • January 28, 2011 Application Submitted in Japan for MP-424 a Novel Chronic Hepatitis C Treatment
  • January 28, 2011 Nycomed and Mitsubishi Tanabe Pharma to Terminate Collaborative Development of APTA-2217, Roflumilast for Treatment of Respiratory Diseases in Japanese Market
  • December 20, 2010 Application Submitted in Japan for FTY720, a Novel Multiple Sclerosis Treatment
  • December 14, 2010 Commencement of R&D Partnership with Anaphore for Atrimer™ Technology (Novel Trivalent Proteins)
  • October 27, 2010 Approval of additional indication of Venoglobulin® IH 5% I.V., human immunoglobulin G for the treatment of polymyositis and dermatomyositis
  • September 28, 2010 Novartis gains NDA approval for FTY720 in the US
  • July 23, 2010 Approval for Partial Changes in Indications, Dosage and Usage, as well as New 1000 mg Dosage Formulation, for Injectable New Quinolone Antibacterial Agents, Pasil® and Pazucross®
  • June 18, 2010 Approval of Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors
  • June 18, 2010 Approval for Additional Indication of Ulcerative Colitis for Remicade I.V. Drip Infusion 100, Anti-Human TNF α Monoclonal-Antibody
  • January 20, 2010 Approval for Additional Indication of Psoriasis for Remicade® I.V. Drip Infusion 100, Anti-Human TNF-α Monoclonal-Antibody
  • January 19, 2010 Approval for New Dosage Form of RADICUT®, Cerebral Neuroprotectant "RADICUT® BAG for I.V. infusion 30mg"

Tanabe Pharma issues its news to provide stakeholders with the latest information related to the Company. Information on products or drug candidates may be included, but is intended to provide for the media, etc. It is not intended for promotion, advertising or medical advice. Information is current as of the date of issue of the individual news. Please be advised that information may be outdated after that point.

  1. Tanabe Pharma Corporation
  2. R&D
  3. R&D News
  • header-content
  • header-content

  • CLOSE
  • MENU

Site Search

If you agree to the use of cookies, please click the "Agree" button.
If you do not agree, please do not use this site. For details, please refer to the following page.

Privacy Policy

Agree

URL
 

田辺ファーマ株式会社のサイトを離れます。よろしいですか？
（別ウィンドウが開きます）

You are leaving the Tanabe Pharma Corporation’s website.
(A new window will be opened.)

はい / O.K.
いいえ / Cancel
  • footer-content